BioWorld

Aug. 3, 2009

View Archived Issues

Study Shows Mechanism Behind Allergy-Promoting TH2 Bias

House Panel Supports 12 Years Data Exclusivity, CER Limits

Cethromycin Pact Likely Waits as FDA Wants New CAP Trial

Other News To Note

Earnings Roundup

Clinic Roundup

So Much for Summer Slump: July Financings Keep Pace

While biotech financing lagged in the first quarter, activity picked up in the second quarter, and it looks as if the third quarter is off to a fairly decent start. (BioWorld Today) Read More

FDA Clears Anadys HCV Study; Good Data Could Lure Partner

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...